Adaptimmune Therapeutics PLC (ADAPY): Shares Outstanding
Not updated since 2024-12-31. No annual report in US GAAP has been filed since. Companies that switch to IFRS reporting, as many foreign filers do, or stop filing are not updated here.
1.54B
As of 2024-12-31
1.59B
As of 2025-06-30
+18.3%
3-year compound annual growth
| Period ended | Shares Outstanding | Change YoY | Source filing |
|---|---|---|---|
| 2024-12-31 | 1.54B | +12.7% | 2025-03-24, Balance as of period end |
| 2023-12-31 | 1.36B | +38.1% | 2025-03-24, Balance as of period end |
| 2022-12-31 | 987.11M | +6.3% | 2024-03-06, Balance as of period end |
| 2021-12-31 | 928.55M | 0.0% | 2023-03-06, Balance as of period end |
| 2020-12-31 | 928.75M | n/c | 2022-03-14, Balance as of period end |
| 2019-12-31 | 631.00M | +0.6% | 2021-02-25, Balance as of period end |
| 2018-12-31 | 627.45M | +11.6% | 2020-02-27, Balance as of period end |
| 2017-12-31 | 562.12M | +32.3% | 2019-02-27, Balance as of period end |
| 2016-12-31 | 424.78M | 0.0% | 2018-03-15, Balance as of period end |
| 2015-12-31 | 424.71M | n/a | 2017-03-13, Balance as of period end |
| 2015-06-30 | 424.71M | n/a | 2017-03-13, Balance as of period end |